Anxiety Management with Vistaril (Hydroxyzine)

Introduction to Anxiety Treatment

The American College of Oncology recommends reserving Vistaril (hydroxyzine) as a second-line or alternative pharmacologic option for anxiety, used only when first-line psychological/behavioral treatments are inaccessible, when patients prefer medication, or when evidence-based therapies have failed 1, 2, 3

For patients with moderate anxiety symptoms, the American College of Oncology prioritizes non-pharmacologic interventions, including Cognitive Behavioral Therapy (CBT), Behavioral Activation (BA), structured physical activity and exercise, and psychosocial interventions with empirically supported components 1, 2, 4, 5
The American College of Oncology recommends offering pharmacologic regimens, including hydroxyzine, only when patients lack access to first-line psychological/behavioral treatments, patients express a preference for pharmacotherapy, or patients have not improved following first-line management 1, 2, 3, 6

The American College of Oncology suggests screening and assessing anxiety severity using validated measures 6
The American College of Oncology recommends providing patient education about anxiety symptoms, commonality, and when to contact the medical team 2, 3, 5
For moderate anxiety, the American College of Oncology recommends offering CBT, BA, structured exercise, or psychosocial interventions as first-line treatments 1, 2
The American College of Oncology advises considering hydroxyzine only if first-line treatments are unavailable or have failed, if there is a patient preference for medication, or if short-term use is anticipated 1, 2, 3

The evidence quality for pharmacologic management of anxiety, including hydroxyzine, is LOW, with only a WEAK strength of recommendation 1, 2, 3
The American College of Oncology notes that hydroxyzine cannot be recommended as a reliable first-line treatment due to high risk of bias in included studies, small sample sizes, and limited number of trials 7